MEDSIR, an international company specializing in independent clinical research in oncology based in Barcelona (Spain) and Jersey City (USA) and REVEAL GENOMICS®, a biotechnology start-up business promoting precision oncology through biomarker innovation, have entered into a strategic agreement for the purpose of reinforcing the scientific value of clinical studies on cancer.
Through the implementation of REVEAL GENOMICS® technology and access to tumor samples and clinical data obtained by MEDSIR, the agreement will boost the application of precision oncology in clinical trials, optimizing their design, contributing to the development of pharmaceuticals and driving translational research and diagnostic innovation.
REVEAL GENOMICS® uses innovative tools to identify optimal therapies based on pioneering techniques and sophisticated methods like machine learning. In this regard, it is important to stress that the company not only reveals new biomarkers, but also develops and implements them in clinical practice such as diagnostic testing.
According to María Campos, CEO of MEDSIR, “we have chosen REVEAL GENOMICS® as our travel companion to enhance the scientific value of the many clinical studies on cancer promoted by MEDSIR”. Moreover, Campos added that “the active collaboration of MEDSIR and REVEAL GENOMICS has reached a stage of maturity, such that its scientific excellence will add exponential value to our disruptive research model, helping to identify new evidence in cancer research”.
On his part, Dr, Aleix Prat, CSO and co-founder of REVEAL GENOMICS®, has stated that “MEDSIR and REVEAL GENOMICS® share a similar vision based on improving patient care through the implementation of precision oncology in clinical practice. Together we will be able to accelerate innovation by blending our experience with knowledge and hard work”.
Prat also added that “this partnership will contribute indisputable value to REVEAL GENOMICS®, by accelerating our goal to change the way in which biomarkers are routinely used in oncology”.
From her side, Dr. Patricia Villagrasa-González, CEO and co-founder of REVEAL GENOMICS® commented: “This collaboration represents a step forward in our mission to provide excellent diagnoses in order to offer excellent therapies for breast cancer and other types of tumors”. Dr. Javier Cortés, Director of the International Breast Cancer Center (IBCC) and co-founder of MEDSIR, added that “The expansion of our collaboration network is a great opportunity to help speed up our growing portfolio, working together to design more brilliant clinical studies to provide new therapies for cancer patients with a faster turnaround”.
Validation of HER2DX®️ in the PHERGain study
HER2DX®️ is the world’s first diagnostic test specifically designed for HER2+ breast cancer. Marketed by REVEAL GENOMICS® since January 2022, HER2DX® is a standardized test that measures the expression of 27 genes in patients with early-stage HER2+ breast cancer.
HER2DX®️ will be applied retrospectively in MEDSIR’s PHERGain and PHERGain-2 studies, evaluating the early metabolic effects of neoadjuvant therapy with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymphatic ganglia and its predictive value for pathological complete response (pCR) in breast and axilla.
The PHERGain and PHERGain-2 studies also evaluate 3-year invasive disease-free survival (iDFS) in patients with HER2+ breast cancer treated with trastuzumab and pertuzumab (and endocrine therapy, if indicated) without chemotherapy.
This initiative helps the corporations consolidate their support of precision oncology, based on the understanding of tumor behavior, through data analysis and the creation of algorithms.